Mutation and expression of LEF1 in adult acute lymphocytic leukemia and their clinical significance.
10.7534/j.issn.1009-2137.2014.05.004
- Author:
Juan LIU
1
;
Xing GUO
1
;
Zheng GE
2
;
Run ZHANG
1
;
Jing-Yan XU
3
;
Min LI
1
;
Yu-Jie WU
1
;
Chun QIAO
1
;
Hai-Rong QIU
1
;
Jian-Fu ZHANG
1
;
Jian-Yong LI
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People Hospital, Nanjing 210029, Jiangsu Province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People Hospital, Nanjing 210029, Jiangsu Province, China. E-mail: Gezheng2008@163.com.
3. Department of Hematology, The Affiliated Hospital of Nanjing University Medical School, Nanjing Drum Tower Hospital, Nanjing 210008, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Exons;
Gene Expression Regulation, Leukemic;
Humans;
Lymphoid Enhancer-Binding Factor 1;
genetics;
Mutation;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics
- From:
Journal of Experimental Hematology
2014;22(5):1212-1216
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoid enhancer factor 1 (LEF1) is a key transcription factor in Wingless-type (Wnt) pathway. The present study was aimed to explore the genetic mutation and expression of LEF1, and their clinical significance in adult patients with acute lymphocytic leukemia (ALL). Genomic DNA was amplified and sequenced to detect the mutation of LEF1 in 131 newly diagnosed adult patients with ALL. Quantitative PCR (qPCR) was performed to detect the expression of LEF1. Moreover, the correlations between mutations and expression of LEF1 with clinical characteristics were analyzed. The results showed that the frequency of LEF1 mutation in adult ALL was 3.1% (4/131) and all of them were point mutations located in exon 2 and 3; the median white blood cell count and median percentage of blasts at diagnosis were significantly higher in LEF1 high expression group than in low expression group (70.6 × 10⁹/L vs 26.2 × 10⁹/L)(P = 0.010); (81.0% vs 57.0%) (P = 0.014); in addition, the percentage of patients with Philadelphia chromosome positive and patients in high-risk group significantly increased in LEF1 high expression group compared with that in low expression group (66.7% vs 36.5%) (P = 0.038); (79.2% vs 56.2%) (P = 0.044). It is concluded that high expression of LEF1 may play an important role on development of adult ALL.
